Validation of a personalised medicine tool for Multiple Myeloma that predicts treatment effectiveness in patients

Project Information

MMpredict

Grant agreement ID: 701143

DOI 10.3030/701143

Project closed

EC signature date 30 October 2016

Start date 1 November 2016

End date 31 October 2020

Funded under

• Horizon 2020 Framework Programme

Total cost € 3 755 802,50

EU contribution € 2 949 027,50

Coordinated by

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands

Deliverables

Websites, patent fillings, videos etc. (1)

Promotional and educational material for stakeholders

Promotional and educational material for stakeholders.

Documents, reports (2)

Scientific articles for peer-reviewed journals

Scientific articles for peer-reviewed journals.

Treatment decision matrix

Publications

Peer reviewed articles (2)

Analytical Validation of SKY92 for the Identification of High-Risk Multiple Myeloma

Author(s): Erik H. van Beers, Daphne Huigh, Lizanne Bosman, Leonie de Best, Rowan Kuiper, Marieke Spaan, Mark van Duin, Pieter Sonneveld, Belinda Dumee, Martin H. van Vliet
Published in: The Journal of Molecular Diagnostics, Issue Online ahead of print., 2020, Page(s) Online ahead of print., ISSN 1525-1578
Publisher: American Society for Investigative Pathology
DOI: 10.1016/j.jmoldx.2020.10.010

Prognostic and Predictive Performance of SKY92 Combined with R-ISS in Elderly Multiple Myeloma Patients in The Hovon-87/NMSG-18 Study

Author(s): Rowan Kuiper, Annemiek Broijl, Mark van Duin, Martin H. van Vliet, Mark-David Levin, Erik H. van Beers, Bronno Van der Holt, Heleen Visser, Markus Hansson, Annette W.G. van der Velden, Belinda Dumee, Michael Vermeulen, Jasper Koenders, H. Berna Beverloo, Marian Stevens-Kroef, Pieter Sonneveld, Anders Waage, Sonja Zweegman
Published in: Clinical Lymphoma Myeloma and Leukemia, Issue 19/10, 2019, Page(s) e10-e11, ISSN 2152-2650
Publisher: Elsevier
DOI: 10.1016/j.clml.2019.09.014